Mei Baisong
Known title: SVP, CHIEF MEDICAL OFFICERCIK: 0001938499
Associated companies
Transaction History
| EDIT | ▼ Sell | Open Market | 541 | $1K | 12/3/2024 | View on chart |
| EDIT | ▼ Sell | Open Market | 518 | $2K | 9/4/2024 | View on chart |
| EDIT | ▼ Sell | Open Market | 6,619 | $34K | 7/19/2024 | View on chart |
| EDIT | ▼ Sell | Open Market | 511 | $3K | 6/4/2024 | View on chart |
| EDIT | ▼ Sell | Open Market | 20,327 | $191K | 3/4/2024 | View on chart |
| EDIT | ▲ Buy | Grant | 50,900 | $0 | 3/2/2024 | View on chart |
| EDIT | ▲ Buy | Grant | 19,458 | $0 | 3/2/2024 | View on chart |
| EDIT | ▲ Buy | Grant | 19,457 | $0 | 3/2/2024 | View on chart |
| EDIT | ▼ Sell | Open Market | 4,317 | $38K | 7/19/2023 | View on chart |
| EDIT | ▲ Buy | Grant | 18,000 | $0 | 3/2/2023 | View on chart |
| EDIT | ▲ Buy | Grant | 58,372 | $0 | 7/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Editas Medicine upgraded to Buy with $5 price target
Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.
Editas Medicine upgraded to Buy with $5 price target. Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.